Table 3.

Straczek et al., 2005; ESTHER study group—adjusted OR according to age, clinical center, and BMI for VTE

	No treatment (OR; 95% CI)	Oral estrogen (OR; 95% CI)	Transdermal estrogen (OR; 95% CI)
No mutations	1	4.1 (2.4–7.1)	1.2 (0.8–1.8)
One of the mutations*	4.1 (2.3–7.4)	25.5 (6.9–95)	4.4 (2.0–9.9)
Factor V Leiden mutation	3.2 (2.0–5.0)	6.3 (1.4–27.6)**	1.8 (0.5–6.3)**
Prothrombin mutation	4.8 (2.6–10.3)	/	1.5 (0.1–2.2)***

OR odds ratio, CI confidence interval, BMI body mass index, VTE venous thromboembolism

*compared to women with no mutation and no treatment **compared to women who have a factor V mutation and not used HRT; ***compared to women who have a prothrombin mutation and not used HRT